Atlas FDA

ABBOTT HAVAB/HAVAB EIA/IMX HAVAB

FDA premarket approval P780012/S012 · decided 2002-09-05

Approval details

PMA number
P780012
Supplement
S012
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
ABBOTT HAVAB/HAVAB EIA/IMX HAVAB
Generic name
Hepatitis a test (antibody and igm antibody)
Applicant
Abbott Laboratories
Date received
2001-10-04
Decision date
2002-09-05
Days to decision
336 days
Decision code
OK30
Product code
LOL
Advisory committee
Microbiology
Expedited review
No
Location
Abbott Park, IL
Statement
ADDITION OF A MANUFACTURERS WORKING CELL BANK (MWCB) AND LIMITING THE NUMBER OF CELL PASSAGES THAT CAN BE PERFORMED FOR ANTIGEN PRODUCTION USING CELLS FROM THE NEW MWCB.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Anti-HCV Next (K252424)Abbott Laboratories2026-04-28
ARCHITECT iGentamicin (K243500)Abbott Laboratories2025-07-09
Alinity i Rubella IgG (K243168)Abbott Laboratories2025-06-20
Alinity h-series System (K243283)Abbott Laboratories2025-02-20
Alinity i Toxo IgM (K233932)Abbott Laboratories2024-08-30
TBI (K232669)Abbott Laboratories2023-09-29
HAVAb IgG II (K222850)Abbott Laboratories2023-08-10
Alinity h-series System (K220031)Abbott Laboratories2023-08-04